The chemistry and biological activity of acyl glucuronides

Current Opinion in Drug Discovery and Development

Volumn 10, Issue 1, 2007, Pages 58-66

  Stachulski, Andrew V ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Acyl migration; Amadori rearrangement; Glucuronide; Selective acylation; Transacylation; UDPGT

Indexed keywords

ACYL GLUCURONIDE; ANTILIPEMIC AGENT; APREPITANT; CARBOXYLIC ACID DERIVATIVE; CLOFIBRIC ACID; DICLOFENAC; GEMCABENE; GEMFIBROZIL; GLUTATHIONE; HYDRATROPIC ACID; IBUPROFEN; MURAGLITAZAR; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN INHIBITOR; SUBSTANCE P ANTAGONIST; TESAGLITAZAR; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR ANTAGONIST; ZOMEPIRAC;

ANALYTIC METHOD; BIOSYNTHESIS; CHEMICAL REACTION; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; THERAPY EFFECT;

ACYLATION; ANIMALS; CARBOXYLIC ACIDS; GLUCURONIDES; HUMANS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PPAR ALPHA; PPAR GAMMA;

EID: 33947302394     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Calegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O'Donnell JP et al: A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab (2005) 6(3):161-225. •• An extremely useful summary of metabolic pathways written from the medicinal chemist's perspective. The aim is to provide a resource showing all known pathways of metabolic activation leading to reactive and, especially, electrophilic species.
2. Kroemer HK, Klotz U: Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet (1992) 23(4):292-310.
3. Kaspersen FM, Van Boeckel CA: A review of the methods of chemical synthesis of sulphate and glucuronide conjugates. Xenobiotica (1987) 17(12):1451-1471.
4. Bock KW: Vertebrate UDP-glucuronosyltransferases: Functional and evolutionary aspects. Biochem Pharmacol (2003) 66(5):691-696.
5. A receptor antagonist and diclofenac in human liver microsomes: Aglycone-dependent UDP-sugar selectivity. Drug Metab Dispos (2005) 33(12):1796- 1802.
6. Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, King C: Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. Arch Biochem Biophys (2004) 424(2):219-225.
7. Goebel WF: Derivatives of glucuronic acid. VIII. The structure of benzoylglucuronic acid. J Biol Chem (1938) 122(2):649-653.
8. Spahn-Langguth H, Benet LZ: Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev (1992) 24(1):5-47. •• A classic review that presents the reactivity pathways of AGs. The major chemical pathways of hydrolysis, acyl migration and protein interaction through reaction with amines are highlighted.
9. Wang M, Dickinson RG: Disposition and covalent binding of diflunisal and diflunisal acyl glucuronide in the isolated perfused rat liver. Drug Metab Dispos (1998) 26(2):98-104.
10. Kenny JR, Maggs JL, Meng X, Sinnott D, Clarke SE, Park BK, Stachulski AV: Synthesis and characterisations of the acyl glucuronide and hydroxy metabolites of diclofenac. J Med Chem (2004) 47(11):2816-2825.
11. Presle N, Lapicque F, Fournel-Gigleux S, Magdalou J, Netter P: Stereoselective irreversible binding of ketoprofen glucuronides to albumin. Characterization of the site and the mechanism. Drug Metab Dispos (1996) 24(10):1050-1057.
12. Ebner T, Heinzel G, Prox A, Beschk K, Wachsmuth H: Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab Dispos (1999) 27(10):1143-1149.
13. Shipkova M, Armstrong VW, Oellerich M, Wieland E: Acyl glucuronide drug metabolites: Toxicological and analytical implications. Ther Drug Monit (2003) 25(1):1-16. • Seminal discussion of the potential toxicity of AGs through interaction with proteins. Chromatographic quantification of AGs and their interaction with proteins are presented.
14. Stachulski AV, Harding JR, Lindon JC, Maggs JL, Park BK, Wilson ID: Acyl glucuronides: Biological activity, chemical reactivity and chemical synthesis. J Med Chem (2006) 49(24):6931-6945.
15. Vanderhoeven SJ, Lindon JC, Troke J, Tranter GE, Wilson ID, Nicholson JK: NMR and QSAR studies on the transacylation reactivity of model 1β-O-acyl glucuronides. I: Design, synthesis and degradation rate measurement. Xenobiotica (2004) 34(1):73-85.
16. Perrie JA, Harding JR, Holt DW, Johnston A, Meath P, Stachulski AV: Effective synthesis of 1β-acyl glucuronides by selective acylation. Org Lett (2005) 7(13):2591-2594. • An important advance in synthetic methodology that has made a wide range of therapeutic AGs more readily accessible is reported. The exploitation of the kinetic anomeric effect which leads almost entirely to the desired 1 β-isomer is highlighted.
17. Sidelmann UG, Gavaghan C, Carless HA, Spraul M, Hofmann M, Lindon JC, Wilson ID, Nicholson JK: 750 MHz directly coupled HPLC-1H NMR: Application for sequential characterisation of the positional isomers and anomers of 2-, 3- and 4-fluorobenzoic acid glucuronides in equilibrium mixtures. Anal Chem (1995) 67(24):4441-4445.
18. 1H-NMR spectroscopy. Xenobiotica (2005) 35:715-725.
19. Vanderhoeven SJ, Lindon J, Troke J, Nicholson JK, Wilson ID: NMR spectroscopic studies of the transacylation reactivity of ibuprofen 1-β-O-acyl glucuronide. J Pharm Biomed Anal (2006) 41(3):1002-1006.
20. Vanderhoeven SJ, Troke J, Tranter GE, Wilson ID, Nicholson JK, Lindon JC: Nuclear magnetic resonance (NMR) and quantitative structure-activity relationship (QSAR) studies on the transacylation reactivity of model 1β-O-acyl glucuronides. II: QSAR modelling of the reaction using both computational and experimental NMR parameters. Xenobiotica (2004) 34(10):889-900. • An important QSAR study of the reactivity of a set of benzoyl AGs.
21. 1H NMR and high-performance liquid chromatography-UV. Drug Metab Dispos (2001) 29(4 Pt 1):375-380.
22. Hasegawa H, Akira K, Shinohara Y, Kasuya Y, Hashimoto T: Kinetics of intramolecular acyl migration of 1β-O-acyl glucuronides of (R)- and (S)-2-phenylpropionic acids. Biol Pharm Bull (2001) 24(7)852-855.
23. Riffel KA, Groff MA, Wenning L, Song H, Lo M-W: Fully automated liquid-liquid extraction for the determination of a novel insulin sensitizer in human plasma by heated nebulizer and turbo ionspray liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci (2005) 819(2):293-300.
24. Valaskovic GA, Utley L, Lee MS, Wu JT: Ultra-low flow nanospray for the normalization of conventional liquid chromatography/mass spectrometry through equimolar response: Standard-free quantitative estimation of metabolite levels in drug discovery. Rapid Commun Mass Spectrom (2006) 20(7):1087-1096.
25. Hansen SH, Christiansen I: Separation of isomers of acyl glucuronides using micellar electrokinetic capillary chromatography in dynamic coated capillaries. Electrophoresis (2004) 25(18-19):3277-3281.
26. Stachulski AV, Jenkins GN: The synthesis of O-glucuronides. Nat Prod Rep (1998) 15(2):173-188.
27. Akin A, Curran TT: Preparation of CI-1027 glucuronide: Metabolite of a remarkable lipid-modulating agent. Synth Commun (2005) 35(12):1649-1661.
28. Juteau H, Gareau Y, Labelle M: A convenient synthesis of β-acyl glucuronides. Tetrahedron Lett (1997) 38(9):1481-1484.
29. Bowkett ER, Park BK, Stachulski AV: Efficient synthesis of 1β-O-acyl glucuronides via selective acylation of allyl or benzyl D-glucuronate. J Med Chem: manuscript in preparation.
30. Kittleman M, Rheinegger U, Espigat A, Oberer L, Aichholz R, Francotte E, Ghisalba O: Preparative enzymatic synthesis of the acylglucuronide of mycophenolic acid. Adv Synth Catal (2003) 345(6-7):825-829.
31. Baba A, Yoshioka T: Synthesis of 1β-O-acyl glucuronides of diclofenac, mefenamic acid and (S)-naproxen by the chemoselective enzymatic removal of protecting groups. Org Biomol Chem (2006) 4(10): 3303-3310.
32. Fenselau C: Acyl glucuronides as chemically reactive intermediates. In: Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity. Kaufmann FC (Ed), Springer-Verlag, Berlin, Germany (1994):367-389.
33. Wang J, Davis M, Li F, Azam F, Scatina J, Talaat R: A novel approach for predicting acyl glucuronide reactivity via Schiff base formation: Development of rapidly formed peptide adducts for LC/MS/MS measurements. Chem Res Toxicol (2004) 17(9):1206-1216. • A significant new assay of AG reactivity with convenient measurement of adducts.
34. Akira K, Uchijima T, Hashimoto T: Rapid internal acyl migration and protein binding of synthetic probenecid glucuronides. Chem Res Toxicol (2002) 15(6):765-772.
35. Bowkett ER, Iddon L, Maggs J, Meng X, Park BK, Stachulski AV: Reactive metabolites: Effective synthesis of 1β-O-acyl glucuronides by selective acylation. 9th European ISSX Meeting, Manchester, UK, 2006.
36. Bailey MJ, Dickinson RG: Acyl glucuronide reactivity in perspective: Biological consequences. Chem Biol Interact (2003) 145(2):117-137. • A broad review of the interaction of AGs with biomolecules.
37. Siraki AG, Chevaldina T, O'Brien PJ: Application of quantitative structure-activity relationships for acute NSAID cytotoxicity in rat hepatocytes. Chem Biol Interact (2005) 151(3):177-191.
38. Boelsterli UA: Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr Drug Metab (2002) 3(4):439-450.
39. Li C, Benet LZ, Grillo MP: Studies on the chemical reactivity of 2-phenylpropionic acid 1-O-acyl glucuronide and S-acyl-CoA thioester metabolites. Chem Res Toxicol (2002) 15(10):1309- 1317.
40. Li C, Benet LZ, Grillo MP: Enantioselective covalent binding of 2-phenylpropionic acid to protein in vitro in rat hepatocytes. Chem Res Toxicol (2002) 15(11):1480-1487.
41. Shore LJ, Fenselau C, King AR, Dickinson RG: Characterisation and formation of the glutathione conjugate of clofibric acid. Drug Metab Dispos (1995) 23(1):119-123.
42. Olsen J, Li C, Bjornsdottir I, Sidenius U, Hansen SH, Benet LZ: In vitro and in vivo studies on acyl-coenzyme A-dependent bioactivation of zomepirac in rats. Chem Res Toxicol (2005) 18(11):1729-1736.
43. Shackleford DM, Nation RL, Milne RW, Hayball PJ, Evans AM: Stereoselective hepatic disposition of model diastereoisomeric acyl glucuronides. J Pharmacokinet Pharmacodyn (2004) 31(1):1-27.
44. Ito H, Ishiwata S, Kosaka T, Nakashima R, Takeshita H, Negoro S, Maeda M, Ikegawa S: Enantioselective immunorecognition of protein modification with optically active ibuprofen using polyclonal antibody. J Chromatogr B Anal Technol Biomed Life Sci (2004) 806(1):11-17.
45. Cannell GR, Bailey MJ, Dickinson RG: Inhibition of tubulin assembly and covalent binding to microtubular protein by valproic acid glucuronide in vitro. Life Sci (2002) 74(22):2633-2643.
46. Shipkova M, Beck H, Voland A, Armstrong VW, Grone HJ, Oellerich M, Wieland E: Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics (2004) 4(9):2728-2738. • The impact of proteomics on identifying AG targets.
47. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A: Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP 2C8: Implications for drug-drug interactions. Drug Metab Dispos (2006) 34(1):191-197. • Timely reminder that AGs may themselves be substrates for further metabolism.
48. Kochansky CJ, Xia YQ, Wang S, Cato B, Creighton M, Vincent SH, Franklin RB, Reed JR: Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronide. Drug Metab Dispos (2005) 33(12):1894- 1904.
49. Fennell TR, Krol WL, Sumner SC, Snyder RW: Pharmacokinetics of dibutylphthalate in pregnant rats. Toxicol Sci (2004) 82(2):407-418.
50. Sallustio BC, DeGraaf YC, Weekley JS, Burcham PC: Bioactivation of carboxylic acid compounds by UDP-Glucuronosyltransferases to DNA-damaging intermediates: Role of glycoxidation and oxidative stress in genotoxicity. Chem Res Toxicol (2006) 19(5):683-691.
51. Wang L, Zhang D, Swaminathan A, Xue Y, Cheng PT, Wu S, Mosqueda-Garcia R, Aurang C, Everett DW, Humphreys WG: Glucuronidation as a major metabolic clearance pathway of C-14 labeled muraglitazar in humans; metabolic profiles in subjects with or without bile collection. Drug Metab Dispos (2006) 34(3):427-439.
52. Li W, Zhang D, Wang L, Zhang H, Cheng PT, Zhang D, Everett DW, Humphreys WG: Biotransformation of carbon-14 labeled muraglitazar in male mice: Interspecies difference in metabolic pathways leading to unique metabolites. Drug Metab Dispos (2006) 34(5):807-820.
53. Cui D, Subramanian R, Shou M, Yu X, Wallace MA, Braun MP, Arison BH, Yergey JA, Prueksaritanont, T: In vitro and in vivo metabolism of a potent and selective integrin αvβ3 antagonist in rats, dogs and monkeys. Drug Metab Dispos (2004) 32(8):848- 861.
54. Kenny JR, Maggs JL, Tettey JN, Harrel AW, Parker SG, Clarke SE, Park BK: Formation and protein binding of the acyl glucuronide of a leukotriene B4 antagonist (SB-209247): Relation to species differences in hepatotoxicity. Drug Metab Dispos (2005) 33(2):271-281.
55. Giuliano C, Fiore F, Di Marco A, Padron Velazquez J, Bishop A, Bonelli F, Gonzalez-Paz O, Marcucci I, Harper S, Narjes F, Pacini B et al: Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase. Xenobiotica (2005) 35(10-11):1035-1054.
56. Ericsson H, Hamren B, Bergstrand S, Elebring M, Fryklund L, Heijer M, Ohman KP: Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor α/γ agonist, after a single oral and intravenous dose in humans. Drug Metab Dispos (2004) 32(9):923-929.
57. Huskey SE, Dean BJ, Doss GA, Wang Z, Hop CE, Anari R, Finke PE, Robichaud AJ, Zhang M, Wang B, Strauss JR et al: The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. Drug Metab Dispos (2004) 32(2):246-258.
58. 14C] gemopatrilat after oral administration to rats, dogs and humans. Drug Metab Dispos (2006) 34(6):961-970.
59. Herr RJ: 5-Substituted 1H-tetrazoles as carboxylic acid isosteres: Medicinal chemistry and synthetic methods. Bioorg Med Chem (2002) 10(11):3379-3393.